Metamizole

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Metamizole

Examples of brand names: Novalgin [DE]

ATC code: N02BB02

Main use (for orientation): Pain; fever

Documented research summary

Endocannabinoid mechanisms are not established interactions with administered CBD/THC. No reliable direct finding for the pair.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Metamizole: active metabolites, enzyme induction; endogenous cannabinoid signalling possible.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Metamizol AbZ 500 mg tablets, oral, metamizole sodium monohydrate; severe pain, colic, treatment-resistant high fever; from age 15. ATC N02BB02 confirmed. Analgesic, antipyretic, antispasmodic; hypotension, idiosyncratic agranulocytosis and liver injury are relevant intrinsic risks. Endocannabinoid involvement is not the same as an exogenous cannabinoid drug–drug interaction.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [C_LABEL_D0162]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: Metamizol AbZ500mg [C_LABEL_D0162]

Source role [C_PR_41751257]: Scope distinction / context

Statement supported: Overview of endogenous metamizole mechanisms, not a new phytocannabinoid combination study.

Source: Cannabinoid Effects of Metamizol/Dipyrone: A Possible Second Life in Pediatric Anesthesia for a Vintage Drug. [C_PR_41751257]

Source role [C_PR_22172309]: Scope distinction / context

Statement supported: Arachidonoylated metamizole metabolites, not CBD/THC co-administration.

Source: Novel bioactive metabolites of dipyrone (metamizol). [C_PR_22172309]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[C_LABEL_D0162] Metamizol AbZ500mg

Original source / bibliographic reference

Authors: Pharmaceutical company not separately entered in the source field; product / official product information identified by title and URL

Year: 2024

Source type: Product information / SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PR_41751257] Cannabinoid Effects of Metamizol/Dipyrone: A Possible Second Life in Pediatric Anesthesia for a Vintage Drug.

Original source / bibliographic reference

Authors: Vittori A, Di Fabio C, Scardaci A, Smedile F, Mascilini I, Francia E, Cecchetti C, Marinangeli F, Marchetti G, Grimaldi Capitello T, Cascella M.

Year: 2026

Source type: Primary source, abstract read

DOI: 10.3390/biomedicines14020358

PMID: 41751257

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_22172309] Novel bioactive metabolites of dipyrone (metamizol).

Original source / bibliographic reference

Authors: Rogosch T, Sinning C, Podlewski A, Watzer B, Schlosburg J, Lichtman AH, Cascio MG, Bisogno T, Di Marzo V, Nüsing R, Imming P.

Year: 2012

Source type: Primary source, abstract read

DOI: 10.1016/j.bmc.2011.11.028

PMID: 22172309

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility